Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NBSE Stock Summary
Top 10 Correlated ETFs
NBSE
In the News
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is seeking shareholder approval for the liquidation and dissolution of the company.
Cheap Penny Stocks To Buy Now? 3 For Your Watch List
Penny stocks remain an alluring yet high-risk asset class for many novice investors. With share prices under $5, penny stocks appear affordable but bring higher volatility.
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.
Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
NeuBase Therapeutics (NASDAQ: NBSE ) stock is taking off on Wednesday despite a lack of news from the preclinical biopharmaceutical company. There are no new press releases from NeuBase Therapeutics or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023.
What Makes NeuBase (NBSE) a New Strong Buy Stock
NeuBase (NBSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for January 20th
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
Best Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?
Best Penny Stocks To Buy? 6 Under $1 To Watch Now
Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy?
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing.
NBSE Financial details
NBSE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-09-30
Metric | History | 2018-09-30 | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -93.57 | -65.49 | -17.6 | -18.8 | -21.21 | |
Operating cash flow per share | -67.1 | -6.88 | -10.92 | -13.82 | -17.97 | |
Free cash flow per share | -67.1 | -8.22 | -11.65 | -14.88 | -18.27 | |
Cash per share | 26.51 | 24.94 | 32.61 | 38.74 | 14.34 | |
Book value per share | 77.06 | 24.25 | 31.9 | 39.6 | 14.37 | |
Tangible book value per share | 23.25 | 23.9 | 31.9 | 39.6 | 14.37 | |
Share holders equity per share | 77.06 | 24.25 | 31.9 | 39.6 | 14.37 | |
Interest debt per share | -4.2 | 0.61 | 0.15 | 4.82 | 3.73 | |
Market cap | 10.83M | 41.28M | 148.92M | 98.57M | 12.75M | |
Enterprise value | 7.15M | 31.08M | 117.06M | 52.22M | -4.41M | |
P/E ratio | -0.82 | -1.52 | -8.63 | -3.84 | -0.37 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -1.14 | -14.51 | -13.9 | -5.22 | -0.44 | |
PFCF ratio | -1.14 | -12.15 | -13.03 | -4.85 | -0.43 | |
P/B Ratio | 0.99 | 4.12 | 4.76 | 1.82 | 0.55 | |
PTB ratio | 0.99 | 4.12 | 4.76 | 1.82 | 0.55 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.29 | -1.19 | -6.92 | -2.01 | 0.14 | |
EV to operating cash flow | -0.75 | -10.92 | -10.93 | -2.77 | 0.15 | |
EV to free cash flow | -0.75 | -9.15 | -10.24 | -2.57 | 0.15 | |
Earnings yield | -1.22 | -0.66 | -0.12 | -0.26 | -2.68 | |
Free cash flow yield | -0.88 | -0.08 | -0.08 | -0.21 | -2.31 | |
Debt to equity | 0.01 | 0.01 | 0 | 0.12 | 0.26 | |
Debt to assets | 0.01 | 0.01 | 0 | 0.1 | 0.18 | |
Net debt to EBITDA | 1.18 | 0.39 | 1.88 | 1.79 | 0.53 | |
Current ratio | 5.52 | 4.41 | 10.42 | 13.1 | 5.92 | |
Interest coverage | 20.84 | -204.24 | -2.22K | -821.7 | -1.39K | |
Income quality | 0.72 | 0.11 | 0.62 | 0.74 | 0.86 | |
Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.02 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.65 | 0.01 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.19 | 0.07 | 0.08 | 0.02 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -4.31 | -2.56 | -3.57 | -0.37 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 402.79 | 189.04 | 112.38 | 129.43 | 82.81 | |
ROIC | -2.13 | -2.61 | -0.54 | -0.4 | -0.96 | |
Return on tangible assets | -3.3 | -2.19 | -0.5 | -0.4 | -1.05 | |
Graham Net | 21.39 | 18.89 | 29.4 | 31.35 | 8.48 | |
Working capital | 3.27M | 8.53M | 29.66M | 50.73M | 20.48M | |
Tangible asset value | 3.29M | 9.88M | 31.29M | 54.07M | 23.19M | |
Net current asset value | 3.27M | 8.53M | 29.66M | 44.83M | 15.15M | |
Invested capital | 0.01 | 0.01 | 0 | 0.12 | 0.26 | |
Average receivables | 0 | 0 | 0 | 0 | 63.86K | |
Average payables | 0 | 738.58K | 1.49M | 1.66M | 1.83M | |
Average inventory | 0 | 0 | 0 | 0 | -63.86K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 4.2K | 1.96K | 1.15K | 532.83 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | -36.92 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.09 | 0.19 | 0.32 | 0.69 | |
Inventory turnover | 0 | 0 | 0 | 0 | -9.89 | |
ROE | -1.21 | -2.7 | -0.55 | -0.47 | -1.48 | |
Capex per share | 0 | -1.34 | -0.73 | -1.05 | -0.29 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q4
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -4.67 | -3.04 | -2.4 | -2.04 | -0.66 | |
Operating cash flow per share | -4.11 | -3.45 | -2.06 | -2.15 | -0.73 | |
Free cash flow per share | -4.13 | -3.48 | -2.06 | -2.15 | -0.73 | |
Cash per share | 14.34 | 10.53 | 8.25 | 8.71 | 4.56 | |
Book value per share | 14.37 | 11.04 | 8.61 | 6.64 | 3.31 | |
Tangible book value per share | 14.37 | 11.04 | 8.61 | 6.64 | 3.31 | |
Share holders equity per share | 14.37 | 11.04 | 8.61 | 6.64 | 3.31 | |
Interest debt per share | 3.72 | 3.49 | 3.35 | 3.23 | 1.93 | |
Market cap | 12.75M | 6.27M | 6.21M | 3.17M | 2.4M | |
Enterprise value | -4.41M | -5.35M | -2.02M | -6.11M | -4.84M | |
P/E ratio | -0.42 | -0.31 | -0.39 | -0.23 | -0.33 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -1.92 | -1.1 | -1.8 | -0.87 | -1.2 | |
PFCF ratio | -1.91 | -1.09 | -1.79 | -0.87 | -1.2 | |
P/B Ratio | 0.55 | 0.34 | 0.43 | 0.28 | 0.26 | |
PTB ratio | 0.55 | 0.34 | 0.43 | 0.28 | 0.26 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.6 | 1.58 | 0.53 | 1.34 | 1.72 | |
EV to operating cash flow | 0.66 | 0.94 | 0.59 | 1.68 | 2.42 | |
EV to free cash flow | 0.66 | 0.93 | 0.58 | 1.68 | 2.42 | |
Earnings yield | -0.59 | -0.8 | -0.65 | -1.09 | -0.76 | |
Free cash flow yield | -0.52 | -0.91 | -0.56 | -1.15 | -0.83 | |
Debt to equity | 0.26 | 0.32 | 0.39 | 0.49 | 0.58 | |
Debt to assets | 0.18 | 0.23 | 0.26 | 0.25 | 0.29 | |
Net debt to EBITDA | 2.35 | 3.42 | 2.17 | 2.03 | 2.57 | |
Current ratio | 5.92 | 8.37 | 7.4 | 2.53 | 2.87 | |
Interest coverage | -2.87K | -2.46K | -1.77K | -5.05K | 23.06K | |
Income quality | 0.87 | 1.3 | 0.84 | 1.06 | 1.1 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.09 | -0.16 | -0.04 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 38.86 | 27.49 | 21.56 | 17.45 | 7.02 | |
ROIC | -0.22 | -0.18 | -0.16 | -0.1 | -0.12 | |
Return on tangible assets | -0.23 | -0.2 | -0.19 | -0.15 | -0.1 | |
Graham Net | 8.48 | 6.22 | 4.11 | 2.16 | 1.12 | |
Working capital | 20.48M | 15.82M | 12.29M | 9.39M | 8.7M | |
Tangible asset value | 23.19M | 18.22M | 14.45M | 11.25M | 9.14M | |
Net current asset value | 15.15M | 10.61M | 7.2M | 4.43M | 3.87M | |
Invested capital | 0.26 | 0.32 | 0.39 | 0.49 | 0.58 | |
Average receivables | 63.86K | 138.86K | 75.08K | 75 | 0 | |
Average payables | 1.75M | 1.11M | 479.85K | 456.16K | 290.39K | |
Average inventory | -63.86K | 63.79K | 182.31K | 54.66K | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 494.46 | 0 | 176.78 | 95.38 | 93.02 | |
Days of inventory on hand | -34.26 | 0 | 32.75 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.18 | 0 | 0.51 | 0.94 | 0.97 | |
Inventory turnover | -2.63 | 0 | 2.75 | 0 | 0 | |
ROE | -0.33 | -0.28 | -0.28 | -0.31 | -0.2 | |
Capex per share | -0.02 | -0.03 | -0.01 | 0 | 0 |
NBSE Frequently Asked Questions
What is NeuBase Therapeutics, Inc. stock symbol ?
NeuBase Therapeutics, Inc. is a US stock , located in Pittsburgh of Pa and trading under the symbol NBSE
What is NeuBase Therapeutics, Inc. stock quote today ?
NeuBase Therapeutics, Inc. stock price is $0.444 today.
Is NeuBase Therapeutics, Inc. stock public?
Yes, NeuBase Therapeutics, Inc. is a publicly traded company.